Logo image of MNDR

MOBILE-HEALTH NETWORK SOLUTI (MNDR) Stock Fundamental Analysis

NASDAQ:MNDR - Nasdaq - KYG622641176 - Common Stock - Currency: USD

1.332  -0.04 (-2.77%)

After market: 1.36 +0.03 (+2.1%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to MNDR. MNDR was compared to 102 industry peers in the Health Care Providers & Services industry. No worries on liquidiy or solvency for MNDR as it has an excellent financial health rating, but there are worries on the profitability. MNDR is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

MNDR had negative earnings in the past year.
MNDR had a negative operating cash flow in the past year.
MNDR Yearly Net Income VS EBIT VS OCF VS FCFMNDR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 0 -5M -10M -15M

1.2 Ratios

The Return On Assets of MNDR (-214.63%) is worse than 96.08% of its industry peers.
MNDR's Return On Equity of -412.24% is on the low side compared to the rest of the industry. MNDR is outperformed by 81.37% of its industry peers.
Industry RankSector Rank
ROA -214.63%
ROE -412.24%
ROIC N/A
ROA(3y)-96.24%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MNDR Yearly ROA, ROE, ROICMNDR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 200 -200 400 600 800

1.3 Margins

MNDR has a worse Gross Margin (18.18%) than 62.75% of its industry peers.
MNDR's Gross Margin has declined in the last couple of years.
MNDR does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 18.18%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.09%
GM growth 5YN/A
MNDR Yearly Profit, Operating, Gross MarginsMNDR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 0 -50 -100

More info and screens

7

2. Health

2.1 Basic Checks

MNDR does not have a ROIC to compare to the WACC, probably because it is not profitable.
MNDR has more shares outstanding than it did 1 year ago.
MNDR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MNDR Yearly Shares OutstandingMNDR Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 5M 10M
MNDR Yearly Total Debt VS Total AssetsMNDR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

Based on the Altman-Z score of -7.33, we must say that MNDR is in the distress zone and has some risk of bankruptcy.
MNDR's Altman-Z score of -7.33 is on the low side compared to the rest of the industry. MNDR is outperformed by 90.20% of its industry peers.
There is no outstanding debt for MNDR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -7.33
ROIC/WACCN/A
WACC9.13%
MNDR Yearly LT Debt VS Equity VS FCFMNDR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 5M -5M

2.3 Liquidity

MNDR has a Current Ratio of 2.31. This indicates that MNDR is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of MNDR (2.31) is better than 81.37% of its industry peers.
A Quick Ratio of 2.26 indicates that MNDR has no problem at all paying its short term obligations.
MNDR has a better Quick ratio (2.26) than 80.39% of its industry peers.
Industry RankSector Rank
Current Ratio 2.31
Quick Ratio 2.26
MNDR Yearly Current Assets VS Current LiabilitesMNDR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

7

3. Growth

3.1 Past

The earnings per share for MNDR have decreased strongly by -508.64% in the last year.
The Revenue has grown by 89.75% in the past year. This is a very strong growth!
MNDR shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 75.52% yearly.
EPS 1Y (TTM)-508.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-493.66%
Revenue 1Y (TTM)89.75%
Revenue growth 3Y75.52%
Revenue growth 5YN/A
Sales Q2Q%77.38%

3.2 Future

The Earnings Per Share is expected to grow by 42.10% on average over the next years. This is a very strong growth
MNDR is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 78.77% yearly.
EPS Next Y96.15%
EPS Next 2Y42.1%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year81.13%
Revenue Next 2Y78.77%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
MNDR Yearly Revenue VS EstimatesMNDR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 10B 20B 30B 40B
MNDR Yearly EPS VS EstimatesMNDR Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 0 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MNDR. In the last year negative earnings were reported.
Also next year MNDR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MNDR Price Earnings VS Forward Price EarningsMNDR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MNDR Per share dataMNDR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4

4.3 Compensation for Growth

A more expensive valuation may be justified as MNDR's earnings are expected to grow with 42.10% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y42.1%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MNDR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MOBILE-HEALTH NETWORK SOLUTI

NASDAQ:MNDR (6/10/2025, 8:00:01 PM)

After market: 1.36 +0.03 (+2.1%)

1.332

-0.04 (-2.77%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)10-23 2024-10-23
Earnings (Next)N/A N/A
Inst Owners2.21%
Inst Owner Change-7.14%
Ins Owners26.73%
Ins Owner ChangeN/A
Market Cap5.82M
Analysts82.86
Price Target65.28 (4800.9%)
Short Float %4.29%
Short Ratio0.82
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)700%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.28
P/FCF N/A
P/OCF N/A
P/B 1.41
P/tB 1.41
EV/EBITDA N/A
EPS(TTM)-4.83
EYN/A
EPS(NY)-0.04
Fwd EYN/A
FCF(TTM)-1.5
FCFYN/A
OCF(TTM)-1.47
OCFYN/A
SpS4.72
BVpS0.95
TBVpS0.94
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -214.63%
ROE -412.24%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 18.18%
FCFM N/A
ROA(3y)-96.24%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.09%
GM growth 5YN/A
F-Score4
Asset Turnover2.59
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 90.01%
Cap/Sales 0.65%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.31
Quick Ratio 2.26
Altman-Z -7.33
F-Score4
WACC9.13%
ROIC/WACCN/A
Cap/Depr(3y)101.22%
Cap/Depr(5y)N/A
Cap/Sales(3y)1.18%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-508.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-493.66%
EPS Next Y96.15%
EPS Next 2Y42.1%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)89.75%
Revenue growth 3Y75.52%
Revenue growth 5YN/A
Sales Q2Q%77.38%
Revenue Next Year81.13%
Revenue Next 2Y78.77%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-272.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year69.85%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-168.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-184.86%
OCF growth 3YN/A
OCF growth 5YN/A